3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
27
Triple Negative Breast Neoplasms
9
Sarcoma
5
Neoplasm Metastasis
4
Liposarcoma
3
Urinary Bladder Neoplasms
2
Leiomyosarcoma
2
Inflammatory Breast Neoplasms
2
Carcinoma, Transitional Cell
2
Uterine Cervical Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Refractory Solid Tumors
1
Recurrence
1
Metastatic HER2-positive Breast Cancer
1
Inoperable Locally Advanced HER2-Negative Breast Cancer
1
Histiocytoma, Malignant Fibrous
1
Hemangiosarcoma
1
Hemangioendothelioma, Epithelioid
1
HR+HER2- Breast Cancer
1
HER2-low Breast Cancer
1
Fludzoparib" and Anti-angiogenic
1
Colorectal Neoplasms
1
Brest Cancer
1
Brain Neoplasms
1
Advanced Breast Cancer
1
Interventions
Paclitaxel
69
Bevacizumab
62
Carboplatin
53
pembrolizumab
46
olaparib
32
Specimen Handling
27
Gemcitabine
27
Cyclophosphamide
26
Magnetic Resonance Spectroscopy
24
liposomal doxorubicin
22
Cisplatin
21
niraparib
20
Taxes
18
Nivolumab
18
fludarabine
17
Topotecan
17
Biopsy
17
Doxorubicin
14
Immunoglobulin G
12
Fulvestrant
12
Disulfides
12
Oxaliplatin
10
mirvetuximab soravtansine
9
durvalumab
9
aldesleukin
9
Surveys and Questionnaires
9
Ipilimumab
9
Fluorouracil
9
Blood Specimen Collection
9
cemiplimab
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
eribulin
×
1 year
×
Clear all
No trials found.